The Challenges of a Micro-Mobility Startup: Roads, Rails, & Rides

The Microtransit industry is a burgeoning new component of the transportation landscape. In this latest episode of Roads, Rails, & Rides host Jeb Morris sits down with Gene Watson of dtmac.matters, Macon Georgia’s Micro-Mobility advocate, to discuss the various challenges presented with a microtransit service startup.

Macon, GA is a mid-sized city in the heart of Georgia with a fascinating history. Indigenous people settled there as early as 1100 AD and modern history has been recorded in the area since 1809. Educational institutions include Wesleyan College, Mercer University, and Middle Georgia State University to name a few. Large parks, rich music heritage, several museums, and the International Cherry Blossom Festival all combine to create a thriving downtown area prime for a micro-mobility “first mile last mile” initiative. In this segment, Gene describes his efforts working with private investors, Hop On Athens, Macon Transit Authority, and the Macon Convention and Visitors’ Bureau to educate and promote an LSV (Low Speed Vehicle) approach to offsetting the parking challenges faced by an increasing shift in population moving back into the downtown area.

To learn more about the challenges of a microtransit startup working with investors, municipalities, and public-private partnerships for the purpose of providing access mobility to a vibrant and thriving downtown community be sure to tune in to this episode of MarketScale’s Roads, Rails, & Rides.

To keep up with new, insights and more in the transportation industry, stay tuned to MarketScale’s Transportation publication here.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More